News
Public · Published
LH: Q3 growth and stronger guidance lifted the outlook as Biopharma backlog hit $8.92B
Labcorp reported third-quarter revenue growth of 6.9% and adjusted earnings per share of $4.78. The company raised its 2026 revenue and adjusted earnings per share guidance, kept its free cash flow guidance unchanged, and said its Biopharma backlog reached $8.92B.
Published:
Updated:
What happened
Labcorp reported third-quarter revenue growth of 6.9% and adjusted earnings per share of $4.78. The company raised its 2026 revenue and adjusted earnings per share guidance, kept its free cash flow guidance unchanged, and said its Biopharma backlog reached $8.92B.
Confirmed
Global impact / market context
Higher guidance signals management expects more revenue and profit ahead, which can support the stock and future spending plans. The unchanged free cash flow guidance suggests cash generation is steady, while the $8.92B backlog gives visibility into future Biopharma revenue.
Analyst inference
For investors, the mix matters: revenue growth plus higher profit guidance points to improving profit per sale, but flat free cash flow guidance means cash available after spending is not rising. The large Biopharma backlog suggests future work is already contracted.
Analyst inference
What to watch
- Watch whether Labcorp delivers the raised 2026 revenue and adjusted earnings per share guidance, since guidance is a forecast rather than a reported result. Confirmed
- Watch for updates on converting the $8.92B Biopharma backlog into revenue, which means tracking how much booked work is completed and billed. Proposed
- Watch free cash flow, which is cash available after capital spending. Flat guidance means investors should check if higher costs or capital spending absorb profit growth. Analyst inference
Evidence
- Original source link unavailable